succinobucol has been researched along with darapladib in 2 studies
| Studies (succinobucol) | Trials (succinobucol) | Recent Studies (post-2010) (succinobucol) | Studies (darapladib) | Trials (darapladib) | Recent Studies (post-2010) (darapladib) |
|---|---|---|---|---|---|
| 53 | 5 | 16 | 104 | 28 | 81 |
| Protein | Taxonomy | succinobucol (IC50) | darapladib (IC50) |
|---|---|---|---|
| Platelet-activating factor acetylhydrolase | Homo sapiens (human) | 0.0003 | |
| Platelet-activating factor acetylhydrolase | Mus musculus (house mouse) | 0.0003 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inazu, A | 1 |
| Biswal, S | 1 |
1 review(s) available for succinobucol and darapladib
| Article | Year |
|---|---|
[Novel therapy for atherosclerosis and inflammatory vascular disease].
Topics: Acetates; Amides; Apolipoprotein A-I; Atherosclerosis; Benzaldehydes; Blood Proteins; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Drug Design; Esters; Humans; Indoles; Keto Acids; Molecular Targeted Therapy; Oxazolidinones; Oximes; Probucol; Quinazolines; Quinazolinones; Sulfhydryl Compounds | 2011 |
1 other study(ies) available for succinobucol and darapladib
| Article | Year |
|---|---|
Novel cardiovascular drugs in clinical trials.
Topics: Anticholesteremic Agents; Benzaldehydes; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Endothelin Receptor Antagonists; Fibrinolytic Agents; Humans; Immunologic Factors; Isoxazoles; Lipoxygenase Inhibitors; Metalloendopeptidases; Oxazolidinones; Oximes; Phospholipase A2 Inhibitors; Probucol; Pyrimidines; Quinolines; Thiophenes | 2010 |